Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$34.1 million.

  • SAB Biotherapeutics' Net Income towards Common Stockholders fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year increase of 14.91%. This contributed to the annual value of -$34.1 million for FY2024, which is 19.17% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Net Income towards Common Stockholders of -$34.1 million as of FY2024, which was up 19.17% from -$42.2 million recorded in FY2023.
  • SAB Biotherapeutics' Net Income towards Common Stockholders' 5-year high stood at $20.1 million during FY2020, with a 5-year trough of -$42.2 million in FY2023.
  • For the 3-year period, SAB Biotherapeutics' Net Income towards Common Stockholders averaged around -$31.7 million, with its median value being -$34.1 million (2024).
  • As far as peak fluctuations go, SAB Biotherapeutics' Net Income towards Common Stockholders slumped by 185.22% in 2021, and later increased by 19.17% in 2024.
  • SAB Biotherapeutics' Net Income towards Common Stockholders (Yearly) stood at $20.1 million in 2020, then crashed by 185.22% to -$17.1 million in 2021, then fell by 9.31% to -$18.7 million in 2022, then slumped by 125.14% to -$42.2 million in 2023, then increased by 19.17% to -$34.1 million in 2024.